Bimekizumab

Bimekizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL17A, IL17F, IL17AF
Clinical data
Trade namesBimzelx
License data
ATC code
Legal status
Legal status
  • EU: Rx-only [1]
Identifiers
CAS Number
UNII
KEGG

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[1][2] that is used to treat plaque psoriasis.[1]

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[1]

Bimekizumab was approved for medical use in the European Union in August 2021.[1][3]

Medical uses

Bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.[1]

History

This drug is being developed by Belgian pharmaceutical UCB. Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[4] but also secukinumab[5] for the treatment of plaque psoriasis.

Names

Bimekizumab is the international nonproprietary name (INN).[6]

References

  1. 1 2 3 4 5 6 "Bimzelx EPAR". European Medicines Agency (EMA). 23 June 2021. Retrieved 24 August 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ↑ Lim SY, Oon HH (2019-05-13). "Systematic review of immunomodulatory therapies for hidradenitis suppurativa". Biologics. 13: 53–78. doi:10.2147/BTT.S199862. PMC 6526329. PMID 31190730.
  3. ↑ "UCB Announces European Commission Approval of Bimzelx (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 24 August 2021. Retrieved 24 August 2021.
  4. ↑ Warren, Richard B.; Blauvelt, Andrew; Bagel, Jerry; Papp, Kim A.; Yamauchi, Paul; Armstrong, April; Langley, Richard G.; Vanvoorden, Veerle; De Cuyper, Dirk; Cioffi, Christopher; Peterson, Luke (2021-07-08). "Bimekizumab versus Adalimumab in Plaque Psoriasis". New England Journal of Medicine. 385 (2): 130–141. doi:10.1056/NEJMoa2102388. ISSN 0028-4793. PMID 33891379. S2CID 233372177.
  5. ↑ Reich, Kristian; Warren, Richard B.; Lebwohl, Mark; Gooderham, Melinda; Strober, Bruce; Langley, Richard G.; Paul, Carle; De Cuyper, Dirk; Vanvoorden, Veerle; Madden, Cynthia; Cioffi, Christopher (2021-07-08). "Bimekizumab versus Secukinumab in Plaque Psoriasis". New England Journal of Medicine. 385 (2): 142–152. doi:10.1056/NEJMoa2102383. ISSN 0028-4793. PMID 33891380. S2CID 233370455.
  6. ↑ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.

Further reading

  • Reis J, Vender R, Torres T (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–9. doi:10.1007/s40259-019-00361-6. PMID 31172372. S2CID 174812750.
  • "Bimekizumab". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.